GU Oncology Now Editors

GU Oncology Now

Active surveillance (AS) is the standard of care for patients with low-risk prostate cancer (PCa), but recent studies have suggested that it may be a feasible and safe treatment plan for some patients with intermediate-risk disease. To investigate this recommendation, Brooke Namboodri Spratte from the School of Medicine of the University of North Carolina, and other researchers examined trends of AS use in patients with low- and intermediate-risk PCa.Their report, presented at the Society of Urologic Oncology&rsquo;s 22nd Annual Meeting, found that AS in men with intermediate-risk disease has significantly increased in recent years&mdash;particularly in men with Gleason 3+3 disease and prostate-specific antigen (PSA) score of 10 to 20. In fact, the study observed that the proportion of patients with intermediate-risk PCa undergoing AS is nearing that seen in patients with low-risk disease.The study included 27,010 men with low-risk disease (defined as Gleason 3+3 with PSA &lt;10) and 38,133 men with intermediate-risk disease (defined as Gleason 3+4 or PSA &ge;10), with further subgroups of Gleason 3+3 with PSA 10-20, Gleason 3+4 with PSA &lt;10, Gleason 3+4 with PSA 10-20, and Gleason 4+3 with any PSA. AS use was indicated via absence of claims for surgery, radiation, androgen deprivation therapy, or chemotherapy within 12 months of PCa diagnosis.Investigators found that use of AS had significantly increased among all groups except men with Gleason 4+3, which remained steady. Specifically, they reported that rates of AS increased from 28.1% to 67.2% for Gleason 3+3 with PSA &lt;10 (p &lt; 0.0001), from 26.8% to 57.9% for Gleason 3+3 with PSA 10 to 20 (p &lt; 0.0001), from 12.7% to 26.2% for Gleason 3+4 with PSA &lt;10 (p &lt; 0.0001), and from 15.7% to 24.5% for Gleason 3+4 with PSA 10 to 20 (p&lt;0.0001).The findings indicated the importance of Gleason score in selecting treatment, according to Spratte, although she added that &ldquo;additional research is needed to define other determinants of active surveillance in this patient population.&rdquo;

Trends of Active Surveillance Management in Men With Low- and Intermediate-Risk Prostate Cancer

Society of Urologic Oncology 22nd Annual Meeting

SUO Annual Meeting 2021

AS Management for Low- and Intermediate-Risk Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe